Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes by Taniguchi, Hidenori et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Genetics
Open Access Research article
Discovery, linkage disequilibrium and association analyses of 
polymorphisms of the immune complement inhibitor, 
decay-accelerating factor gene (DAF/CD55) in type 1 diabetes
Hidenori Taniguchi, Christopher E Lowe, Jason D Cooper, Deborah J Smyth, 
Rebecca Bailey, Sarah Nutland, Barry C Healy, Alex C Lam, Oliver Burren, 
Neil M Walker, Luc J Smink, Linda S Wicker and John A Todd*
Address: Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical 
Research, University of Cambridge, Hills Road, Cambridge, CB2 2XY, UK
Email: Hidenori Taniguchi - htaniguc@geriat.med.osaka.u.ac.jp; Christopher E Lowe - chris.lowe@cimr.cam.ac.uk; 
Jason D Cooper - jason.cooper@cimr.cam.ac.uk; Deborah J Smyth - debbie.smyth@cimr.cam.ac.uk; 
Rebecca Bailey - rebecca.bailey@cimr.cam.ac.uk; Sarah Nutland - sarah.nutland@cimr.cam.ac.uk; Barry C Healy - barry.healy@cimr.cam.ac.uk; 
Alex C Lam - alex.lam@bbsrc.ac.uk; Oliver Burren - oliver.burren@cimr.cam.ac.uk; Neil M Walker - neil.walker@cimr.cam.ac.uk; 
Luc J Smink - luc.smink@cimr.cam.ac.uk; Linda S Wicker - linda.wicker@cimr.cam.ac.uk; John A Todd* - john.todd@cimr.cam.ac.uk
* Corresponding author    
Abstract
Background: Type 1 diabetes (T1D) is a common autoimmune disease resulting from T-cell
mediated destruction of pancreatic beta cells. Decay accelerating factor (DAF, CD55), a
glycosylphosphatidylinositol-anchored membrane protein, is a candidate for autoimmune disease
susceptibility based on its role in restricting complement activation and evidence that DAF
expression modulates the phenotype of mice models for autoimmune disease. In this study, we
adopt a linkage disequilibrium (LD) mapping approach to test for an association between the DAF
gene and T1D.
Results:  Initially, we used HapMap II genotype data to examine LD across the DAF region.
Additional resequencing was required, identifying 16 novel polymorphisms. Combining both
datasets, a LD mapping approach was adopted to test for association with T1D. Seven tag SNPs
were selected and genotyped in case-control (3,523 cases and 3,817 controls) and family (725
families) collections.
Conclusion: We obtained no evidence of association between T1D and the DAF region in two
independent collections. In addition, we assessed the impact of using only HapMap II genotypes for
the selection of tag SNPs and, based on this study, found that HapMap II genotypes may require
additional SNP discovery for comprehensive LD mapping of some genes in common disease.
Background
T1D is characterised as a common autoimmune disease,
mainly resulting from a T-cell mediated destruction of
pancreatic beta cells that leaves patients completely
dependent on exogenous insulin to regulate their blood
glucose level. T1D is strongly clustered in families with an
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LD map for human DAF region on Chromosome 1q32 Figure 1
LD map for human DAF region on Chromosome 1q32. All markers with the MAF of less than 0.05 or with insufficient 
genotyping data were excluded in the LD measurement. a. LD map with 21 markers genotyped in 60 individuals obtained from 
HapMap II. b. LD map with 22 markers identified by resequencing with 32 CEPH's individuals. figure c. LD map with 38 mark-
ers, a combined dataset of both HapMap II and in-house resequencing data with 32 CEPH's individuals.
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overall genetic risk ratio, an estimate of the familial clus-
tering of the disease, of approximately 15[1]. However, of
the hundreds of association studies reported to date, only
four loci have been identified and successfully replicated:
the HLA class II genes on chromosome 6p21[2]; the insu-
lin gene (INS) on chromosome 11p15[3,4]; CTLA4 on
chromosome 2q33[5,6]; and PTPN22  on chromosome
1p13[7,8]. CD25 on chromosome 10p15 has been impli-
cated, but this finding awaits independent replication[9].
Given that these genes alone cannot explain the familial
clustering of T1D, many other genes remain to be identi-
fied.
Recently, there have been several reports focusing on the
relationship between autoimmune disease and the com-
plement system, which is composed of more than 30 sol-
uble and membrane-bound proteins[10,11] and plays an
important role in innate host defence. As inappropriate
regulation of the complement system can lead to signifi-
cant damage of host tissues[12], a number of membrane-
bound complement regulatory proteins are active, such as
DAF, a glycosylphosphatidylinositol-anchored mem-
brane protein that restricts complement activation by
inhibiting the formation of C3 convertases in both the
classical and alternative pathways[13,14].
Dysfunction of human DAF on erythrocytes contributes
to the paroxysmal nocturnal hemoglobinuria (PNH) by
increasing their sensitivity to complement lysis[13,15,16].
In addition, a proportion of DAF-deficient (Cromer
INAB) patients develop inflammatory bowel disease.
However, little is known about DAFs role in autoimmune
disease in vivo[17].
Recently, it has been reported that DAF modulates T cell
immunity by controlling T cell- and antigen-presenting
cell- induced alternative pathway of C3 activation during
cognate interactions [18-20]. According to gene targeting
studies, mice deficient in the DAF1 gene, the murine
homologue of human DAF, showed more susceptibility to
complement mediated inflammatory injury, especially
DAF1 deficient female mice in a MRL/lpr background, a
model for human systemic lupus erythematosus, which
showed aggravated lymphadenopathy and splenomegaly,
higher serum anti-chromatin autoantibody levels, and
dermatitis[21].
Given this prior evidence, DAF may function as a negative
regulator of autoimmune response by modulating T cell
activity and directly protecting host tissues in vivo and that
recombinant DAF may be an ideal therapeutic agent for
autoimmunity[22]. On the other hand, DAF does not lie
under any of the reported T1D linkage peaks[23,24] nor
have there been any reports of genetic association studies
between DAF and autoimmune disease, although recently
differential expression of DAF was observed when com-
paring T cells from nonobese diabetic (NOD) mice and
diabetes-resistant NOD mice having a congenic interval
containing the DAF gene thereby making it a candidate
gene for the Idd5.4 region (William Ridgway and Linda
Wicker, unpublished observations).
In this study, to elucidate the susceptibility of DAF with
T1D, we performed an association study using a LD map-
ping approach, together with the direct analysis of three
non-synonymous SNPs (nsSNPs) in large case-control
and family collections.
Results
Linkage disequilibrium analysis
Initially, we used phase II genotyping data from the Hap-
Map project[25,26], a catalogue of common human
genetic variants, providing their allele frequencies and
intermarker LD patterns among people, within and
among populations from African, Asian, and European
ancestry. In the DAF region, about 40 kb on chromosome
1q32, 21 common SNPs (minor allele frequency (MAF) ≥
0.05), have been genotyped in 60 U.S.A. residents with
northern and western European ancestry, collected in
1980 by the Centre d'Etude du Polymorphisme Humain
(CEPH, CEU). We note that all of these SNPs were located
in non-coding regions and that the average inter-SNP dis-
tance was 2 kb. A LD map of the region, using pairwise D',
shows little evidence of recombination within the region
(Figure 1a).
DAF resequencing
As we were concerned about adopting a LD mapping
approach given the HapMap SNP density[27], we rese-
quenced DAF in 32 CEPH individuals, selected from the
60 CEPH individuals used by the HapMap project, to
increase the SNP density across the region.
Analysis of the resequencing data identified 32 polymor-
phisms, 26 of which were SNPs and six were deletion/
insertion polymorphisms (DIPs), of which 12 SNPs and
four DIPs were novel when compared to dbSNP build 125
(Table 1). Twenty-two polymorphisms were common
(MAF ≥ 0.05), five of which were also found in the Hap-
Map II data. The relatively small number of common pol-
ymorphisms found in both datasets is not unexpected, as
HapMap II SNPs were selected to provide an even cover-
age in terms of distance across the genome, whereas the
resequencing is focused on regions of interest and extracts
all common polymorphisms present in these individuals.
A LD map of the region, based on these 22 polymor-
phisms (Figure 1b), revealed additional evidence of
recombination within the region over and above that
apparent in HapMap II data alone (Figure 1a). There wasBMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
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Table 1: Polymorphisms identified in human DAF. Map positions on human chromosome 1 were from NCBI build 35. Selected tag 
SNPs are in boldface. Alleles are coded Major > Minor. MAF calculated from the 32 individuals used for tag SNP selection, except for 
nsSNPs, in which case the MAF is calculated from genotyped controls. DIL = identified by in-house resequencing, HapMap = identified 
in HapMap II dataset, DIL&HapMap II = Identified in both in-house resequencing and HapMap II dataset.
Polymorphism – dbSNP(build125) Location MA
F
Allelic R2 Dataset
Position(NCBI35) Gene
ss49853051(G > C) 203881344 promoter 0.03 - DIL
ss49853052(C > T) 203881734 promoter 0.03 - DIL
rs6685886(C > A) 203882613 promoter 0.46 85.07 DIL
rs2564978(C > T) 203882811 promoter 0.33 tag SNP DIL & HapMap
rs3841376 (TAGTTACTTCCCCTCCTTCCC > -) 203882879 promoter 0.33 100.00 DIL
ss49853053(A > G) 203883074 promoter 0.26 tag SNP DIL
ss49853054(T > C) 203883723 intron 1 0.02 - DIL
rs7533852(G > T) 203883822 intron 1 0.44 89.15 DIL
ss49853055(TA > -) 203884424 intron 2 0.03 - DIL
rs4844590(C > T) 203884524 intron 2 0.23 tag SNP DIL
rs2782828(G > T) 203885394 intron 2 0.24 94.47 HapMap
ss49853056(A > G) 203886206 intron 2 0.03 - DIL
ss49853057(C > G) 203887670 intron 4 0.13 tag SNP DIL
ss49853058(G > A) 203888427 intron 4 0.03 - DIL
rs4844591(T > C) 203888688 intron 5 0.33 90.27 DIL & HapMap
rs4844592(A > T) 203889606 intron 5 0.33 90.27 HapMap
rs6703002(G > T) 203890767 intron 5 0.32 88.10 HapMap
rs6700168(C > A) 203890929 intron 5 0.38 82.68 HapMap
rs925130(A > G) 203891827 intron 5 0.33 100.00 HapMap
rs925131(G > A) 203892116 intron 5 0.33 90.27 HapMap
ss49853059(C > T) 203892582 intron 5 0.02 - DIL
rs2184476(A > G) 203893064 intron 6 0.45 tag SNP DIL
rs1507757(A > C) 203893143 intron 6 0.35 tag SNP DIL
rs6662070(G > A) 203894104 intron 6 0.31 100.00 HapMap
rs1507758(C > G) 203895876 intron 6 0.33 90.27 HapMap
rs1507759(G > A) 203896023 intron 6 0.32 100.00 HapMap
rs12075906(A > G) 203896494 intron 6 0.33 100.00 HapMap
rs1354942(A > G) 203896887 intron 6 0.33 90.27 HapMap
rs7555030(G > A) 203897125 intron 6 0.33 100.00 HapMap
rs7544288(G > A) 203897417 intron 6 0.41 97.09 HapMap
rs1507760(T > C) 203897760 intron 6 0.33 100.00 HapMap
rs1507761(C > T) 203898194 intron 6 0.33 100.00 HapMap
ss49853060(C > T) 203898910 intron 7 0.04 - DIL
rs10746462(G > A) 203898943 intron 7 0.33 90.27 DIL
rs10746463(A > G) 203898991 intron 7 0.33 90.27 DIL & HapMap
ss49853061(G > A) 203899255 intron 8 0.02 - DIL
rs2135923(G > A) 203914988 intron 10 0.33 90.27 HapMap
ss49853066(- > TT) 203921271 intron 10 0.39 97.09 DIL
ss49853062(A > G) 203922987 3' 0.02 - DIL
rs11120766(A > G) 203923074 3' 0.45 84.94 DIL
rs1507765(A > C) 203923641 3' 0.45 84.94 DIL & HapMap
rs11307618(A > -) 203923723 3' 0.41 97.09 DIL
ss49853063(A > G) 203923730 3' 0.41 97.09 DIL
ss49853064(C > -) 203923933 3' 0.39 91.71 DIL
rs12066318(T > C) 203924026 3' 0.33 tag SNP DIL
ss49853065(- > ATG) 203924418 3' 0.45 84.94 DIL
rs11120769(G > T) 203925240 3' 0.45 83.28 DIL
rs11117564(C > A) 203925366 3' 0.45 90.45 DIL & HapMap
nsSNPs
rs28371588(>) 203884176 Exon 2 0.05 -BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
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a breakdown in LD towards the 5' end of DAF that was not
evident in HapMap II data.
Tag SNP analysis of DAF
To test for an association between T1D and the DAF
region, we adopted a LD mapping approach, which
exploits the non-random relationships between SNPs
(known as LD) in a region of interest to reduce the
amount of genotyping required. As the causal SNP is
unknown, we assume that predicting the causal SNP is
likely to be no more difficult than predicting any other
SNP. The predictive performance of the tag SNPs was
assessed using a R2 measure, which measures the ability to
predict each known SNP by multiple regression on the set
of tag SNPs. The tag SNPs were analysed using a multilo-
cus test, as described by Chapman et al[28], which tests for
an association between the tag SNPs and T1D due to LD
with one or more causal variants[28,29].
We first combined our resequencing data with the Hap-
Map data, providing a panel of 38 common polymor-
phisms genotyped in 32 individuals (Table 1), and
generated a combined LD map of the region (Figure 1c).
Subsequently, seven tag SNPs were selected[9] from the
38 common polymorphisms, required to capture the var-
iation within the DAF  region with a minimum R2 of
0.80[28] (Table 1). The tag SNPs were genotyped in 3,523
cases and 3,817 controls, and in 725 Caucasian multiplex
T1D families (Table 2). The case-control and family mul-
tilocus P-values were 0.12 (3,523 case and 3,817 control
genotypes; F7,7321 = 1.63) and 0.69 (parent-child trio gen-
otypes = 1,390; χ7
2 = 4.72), respectively, providing no evi-
dence for the association between T1D and the DAF
region. In the case-control collection, the multilocus test
was stratified by broad geographical within the UK in
order to minimize any confounding due to variation in
allele frequencies across Great Britain[9,30].
DAF-WESa/b(T > G) 203884266 Exon 2 0.00
55
-
rs12135160(>) 203899090 Exon 8 - -
Table 1: Polymorphisms identified in human DAF. Map positions on human chromosome 1 were from NCBI build 35. Selected tag 
SNPs are in boldface. Alleles are coded Major > Minor. MAF calculated from the 32 individuals used for tag SNP selection, except for 
nsSNPs, in which case the MAF is calculated from genotyped controls. DIL = identified by in-house resequencing, HapMap = identified 
in HapMap II dataset, DIL&HapMap II = Identified in both in-house resequencing and HapMap II dataset. (Continued)
Table 2: Genotyping data of tag SNPs. The number of individuals with each genotype in case-control data and the number of alleles in 
family data are indicated. T, Transmitted. UT, Untransmitted. MAF, minor allele frequency calculated from either control samples or 
parents.
Case-Control Family
SNP Population MAF 1/1 1/2 2/2 Population MAF Number of 
Trios
TU T
rs2564978
(C > T)
Case 0.31 1648 1468 318 UK 0.32 738 483 458
Control 0.31 1791 1622 354 USA 0.27 526 272 289
ss4985305
3(A > G)
Case 0.25 1895 1305 219 UK 0.24 736 345 350
Control 0.24 2147 1338 231 USA 0.29 536 317 304
rs4844590
(C > T)
Case 0.23 1987 1194 193 UK 0.21 711 287 309
Control 0.22 2288 1251 195 USA 0.26 517 272 270
ss4985305
7(C > G)
Case 0.07 2914 465 22 UK 0.08 709 113 101
Control 0.08 3071 580 17 USA 0.06 527 62 62
rs2184476
(A > G)
Case 0.31 1607 1447 314 UK 0.33 723 475 442
Control 0.31 1757 1578 345 USA 0.27 492 249 268
rs1507757
(A > C)
Case 0.31 1660 1469 319 UK 0.33 736 484 479
Control 0.31 1756 1586 349 USA 0.27 476 246 248
rs1206631
8(A > G)
Case 0.44 658 1679 1104 UK 0.43 751 866 859
Control 0.45 738 1868 1135 USA 0.44 538 597 605BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
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Analysis of DAF non-synonymous SNPs
Recently, it has been proposed that complex diseases such
as T1D may result from the effects of a large number of
rare variants, with substantial allelic heterogeneity at
causal loci[31,32]. In DAF, several rare non-synonymous
SNPs (nsSNPs) were reported in the exons encoding the
short consensus repeat (SCR) domains of the DAF pro-
tein, which have subsequently been shown to be related
with antigen of the Cromer blood group sys-
tem[13,14,33,34]. On the basis of the rare variant hypoth-
esis, we genotyped three rare nsSNPs in3,490 cases and
3,814 controls (Table 3), under the hypothesis that a rare
functional variant in DAF might have a strong effect in
T1D. The following three nsSNPs were assessed: DAF-
WESa/b(G > T) located in exon 2 with a MAF of 0.0055–
0.0060 in a Finnish population[35,36]; rs28371588(C >
A), also located in exon 2[34]; and, rs12135160(G > A),
identified by SsahaSNP detection tool (NIH and Sanger
Institute, UK) in exon 8 and not previously genotyped. All
result in amino-acid substitutions, but their phenotypic
influences have not been characterized. In the present
study, the MAF of rs12135160(G > A) was 0.00042 in
3,768 controls, and consequently, we have no statistical
power to detect an association. Both rs28371588(C > A)
and DAF-WESa/b(G > T) were monomorphic in the case-
control collection.
Discussion
In this study, we did not find any evidence for an associa-
tion between T1D and the DAF region in large case-con-
trol and family collections using a LD mapping approach.
We combined the HapMap II genotyping data and rese-
quencing data, for the selection of tag SNPs. Had we cho-
sen the tag SNPs using only the HapMap II genotyping
data, only two tag SNPs (rs2564978 and rs1507765) were
required to capture the detected variation within the ~40
kb  DAF  region with a minumum R2 of 0.8. However,
when the predictive performance of the two tag SNPs were
applied to the combined sequence dataset, they no longer
captured the variation within the region to the required
level since seven of the thirty-six common polymor-
phisms had an R2 below 0.8. The inability of the tag SNPs
selected from HapMap II data to tag the combined dataset
(minimum R2 = 0.35) suggests that for the analysis of
localized regions containing candidate genes, as opposed
to whole-genome association studies, HapMap II data
alone may not provide sufficient information to facilitate
a comprehensive LD-mapping approach. In the tag SNP
approach, as the causal variant is unknown, we assume
that the problem of predicting the causal polymorphism
is likely to be no more difficult than that of predicting any
other polymorphism[28]. Consequently, the power of the
tag SNP approach to detect a causal polymorphism is
based upon the minimum R2[28], assuming that the
majority of common polymorphisms in a region are
known. In this instance, incomplete knowledge of the
common polymorphisms in a region inflated the mini-
mum R2, providing false confidence in the ability of the
tag SNPs to capture the variation within a region, and in
the power to detect a causal variant. Our results indicate
that for some genes/regions HapMap II data may need to
be supplemented by additional resequencing data to
allow comprehensive association mapping of common
variants.
Conclusion
We conclude that variation in DAF itself is unlikely to
have a major effect in T1D in these populations. Analysis
of an extended region, surrounding the DAF region ana-
lysed in this study, showed a cluster of several other genes
involved in the complement system, including C4b bind-
ing protein (C4bp) and membrane cofactor protein
(MCP), both known regulators of complement activation
(RCA) genes[11,37,38]. C4bp and MCP restrict comple-
ment activation by inhibiting the formation of C3 conver-
tases in the classical pathways like DAF, suggesting that
they modulate each other in direct and indirect ways. To
clarify the relation of autoimmune disease and comple-
ment system, including DAF, further genetic association
studies and functional studies on RCA genes are needed.
The set of tag SNPs and the LD map for the DAF region
will be useful for such further studies.
Methods
Subjects
The resequencing panel consisted of 32 CEPH individu-
als; Utah residents with ancestry from Northern and West-
Table 3: Genotyping data of non-synonymous SNPs. The numbers of individuals with each genotype in case-control data are indicated. 
MAF, minor allele frequency calculated from control samples.
SNP Population MAF 1/1 1/2 2/2
rs28371588(C > A) Case 0 3420 0 0
Control 0 3748 0 0
DAF-WESa/b(T > G) Case 0 3438 0 0
Control 0 3738 0 0
rs12135160(G > A) Case 0.0004 3437 3 0
Control 0.0004 3765 3 0BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
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ern Europe collected in 1980 by the Centre d'Etude du
Polymorphisme Humain (CEPH).
The 3,523 cases were recruited as part of the Juvenile Dia-
betes Research Foundation/Wellcome Trust Diabetes and
Inflammation Laboratory's United Kingdom Genetic
Resource Investigating Diabetes (U.K. GRID) study, which
is a joint project between the University of Cambridge
Department of Paediatrics and the Department of Medical
Genetics at the Cambridge Institute for Medical Research.
Most cases were < 16 years of age at the time off collection,
all resided in Great Britain, and all were of European
descent (self-reported). The 3,817 control samples were
obtained from the 1958 British Birth Cohort (1958 BBC),
an ongoing follow-up of all person born in Great Britain
during one week in 1958 (National Child Development
Study)[39]. All cases and control were of white ethnicity.
All families were Caucasian and of European descent,
with two parents and at least one affected child. The fam-
ily collection consisted of 457 multiplex families from the
U.K. British Diabetic Association Warren 1 repository[40]
and 268 multiplex families from U.S.A. Human Biological
Data Interchange[41].
The Cambridge Local Research Ethics Committee gave full
ethical approval, and informed consent was obtained for
the collection and use of these DNA samples from all sub-
jects.
DAF resequencing
We first annotated the DAF gene locally[42,43] and dis-
played the annotation through gbrowse[44] within
T1DBase[45], using these annotations we resequenced all
11 exons, exon/intron boundaries and up to 3 kb of 3' and
5' flanking sequence of the DAF gene in 32 CEPH individ-
uals, to increase the SNP density across the region. The
sequencing reactions were carried out on nested PCR
products using Applied Biosystems (ABI) BigDye termina-
tor v3.1 chemistry and the sequences resolved on an
ABI3700 DNA Analyser. Polymorphisms were identified
using the Staden Package [46] and double-scored by a sec-
ond operator.
Statistical analysis
The multilocus test has been described in detail else-
where[9,28,29,47], briefly, for the case-control data, the
multilocus test is essentially Hotellings T2[48,49], in
which we score each diallelic locus as 0, 1 or 2 and com-
pare the mean score vectors between cases and control. In
the case of the family data, the multilocus test takes the
form of a multilocus TDT[28], in which, for each parent,
we calculate a vector whose elements describe transmis-
sions of each of the tag SNPs. If the parent is homozygous
at a locus, the corresponding element is scored as zero,
otherwise it scored as either +1 or -1 depending on which
allele was transmitted. The multilocus test tests the mean
of this vector against zero; it is asymptotically distributed
as a χ2 with degrees of freedom (df) equal to the number
of tag SNPs[28,47].
The program for the selection of tag SNPs[28] and associ-
ation analysis used here are implemented in the Stata sta-
tistical system and may be downloaded from our
website[50].
Genotyping
Genotyping was performed using Taqman MGB (Applied
Biosytems Inc, Foster City, CA)[51]. All genotyping data
were double-scored to minimize error. All genotyping
data were in Hardy-Weinberg equilibrium (P  > 0.05).
Genotyping failure rates for all assays in both the family
and case-control collection were ≤ 6%.
Authors' contributions
HT participated in the design of the study, gene annota-
tion, sequencing, genotyping, data analysis and manu-
script preparation. CEL participated in the design of the
study, genotyping, data analysis and manuscript prepara-
tion. JDC participated in data analysis and manuscript
preparation. DJS and RB participated in genotyping and
sequencing. SN coordinated DNA resources. NMW coor-
dinated data management. LS, BCH, ACL and OB partici-
pated in genome informatics. LSW and JAT participated in
the conception, design and coordination of the study and
participated in manuscript preparation. All authors read
and approved the final manuscript.
Acknowledgements
We gratefully acknowledge the participation of all T1D patients and family 
members. We thank the Human Biological Data Interchange and Diabetes 
U.K. for USA and U.K. multiplex families, respectively. We acknowledge 
use of DNA from the 1958 British Birth Cohort collection, funded by the 
Medical Research Council grant G0000934 and Wellcome Trust grant 
068545/Z/02. DNA samples were prepared by Jayne Hutchings, Gillian 
Coleman, Trupti Mistry, Kirsi Bourget, Sally Clayton, Matthew Hardy, Jen-
nifer Keylock, Pamela Lauder, Meeta Maisuria, William Meadows, Meera 
Sebastian, Sarah Wood, The Avon Longitudinal Study of Parents and Chil-
dren laboratory in Bristol, including Susan Ring, Wendy McArdle, Richard 
Jones, for preparing DNA samples.
References
1. Risch N: Assessing the role of HLA-linked and unlinked deter-
minants of disease.  Am J Hum Genet 1987, 40:1-14.
2. Cucca F, Lampis R, Congia M, Angius E, Nutland S, Bain SC, Barnett
AH, Todd JA: A correlation between the relative predisposi-
tion of MHC class II alleles to type 1 diabetes and the struc-
ture of their proteins.  Hum Mol Genet 2001, 10:2025-2037.
3. Bell GI, Horita S, Karam JH: A polymorphic locus near the
human insulin gene is associated with insulin-dependent dia-
betes mellitus.  Diabetes 1984, 33:176-183.
4. Barratt BJ, Payne F, Lowe CE, Hermann R, Healy BC, Harold D, Con-
cannon P, Gharani N, McCarthy MI, Olavesen MG, McCormack R,
Guja C, Ionescu-Tirgoviste C, Undlien DE, Ronningen KS, Gillespie
KM, Tuomilehto-Wolf E, Tuomilehto J, Bennett  ST, Clayton DG,BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
Page 8 of 9
(page number not for citation purposes)
Cordell HJ, Todd JA: Remapping the insulin gene/IDDM2 locus
in type 1 diabetes.  Diabetes 2004, 53:1884-1889.
5. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C,
Bosi E, Larrad MT, Rios MS, Chow CC, Cockram CS, Jacobs K, Mijo-
vic C, Bain SC, Barnett AH, Vandewalle CL, Schuit F, Gorus FK, Tosi
R, Pozzilli P, Todd JA: The CTLA-4 gene region of chromosome
2q33 is linked to, and associated with, type 1 diabetes. Bel-
gian Diabetes Registry.  Hum Mol Genet 1996, 5:1075-1080.
6. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G,
Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahl-
man I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B,
Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ,
Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker
ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomile-
hto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ron-
ningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP,
Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB,
Wicker LS, Todd JA, Gough SC: Association of the T-cell regula-
tory gene CTLA4 with susceptibility to autoimmune disease.
Nature 2003, 423:506-511.
7. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM,
Vella A, Nutland S, Rance HE, Maier L, Barratt BJ, Guja C, Ionescu-
Tirgoviste C, Savage DA, Dunger DB, Widmer B, Strachan DP, Ring
SM, Walker N, Clayton DG, Twells RC, Gough SC, Todd JA: Repli-
cation of an association betweenthe lymphoid tyrosine phos-
phatase locus (LYP/PTPN22) with type 1 diabetes, and
evidence for its role as a general autoimmunity locus.  Diabe-
tes 2004, 53:3020-3023.
8. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani
M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS,
Comings D, Mustelin T: A functional variant of lymphoid tyro-
sine phosphatase is associated with type I diabetes.  Nat Genet
2004, 36:337-338.
9. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, Jones
R, Ring SM, McArdle W, Pembrey ME, Strachan DP, Dunger DB,
Twells RC, Clayton DG, Todd JA: Localization of a type 1 diabe-
tes locus in the IL2RA/CD25 region by use of tag single-
nucleotide polymorphisms.  Am J Hum Genet 2005, 76:773-779.
10. Miwa T, Song WC: Membrane complement regulatory pro-
teins: insight from animal studies and relevance to human
diseases.  Int Immunopharmacol 2001, 1:445-459.
11. Morgan BP: Regulation of the complement membrane attack
pathway.  Crit Rev Immunol 1999, 19:173-198.
12. Gasque P: Complement: a unique innate immune sensor for
danger signals.  Mol Immunol 2004, 41:1089-1098.
13. Lublin DM: Review: Cromer and DAF: role in health and dis-
ease.  Immunohematol 2005, 21:39-47.
14. Lublin DM, Kompelli S, Storry JR, Reid ME: Molecular basis of
Cromer blood group antigens.  Transfusion 2000, 40:208-213.
15. Storry JR, Reid ME: The Cromer blood group system: a review.
Immunohematol 2002, 18:95-103.
16. Hue-Roye K, Powell VI, Patel G, Lane D, Maguire M, Chung A, Reid
ME: Novel molecular basis of an Inab phenotype.  Immunohema-
tol 2005, 21:53-55.
17. Lin F, Spencer D, Hatala DA, Levine AD, Medof ME: Decay-acceler-
ating factor deficiency increases susceptibility to dextran sul-
fate sodium-induced colitis: role for complement in
inflammatorybowel disease.  J Immunol 2004, 172:3836-3841.
18. Clayton A, Harris CL, Court J, Mason MD, Morgan BP: Antigen-pre-
senting cell exosomes are protected from complement-
mediated lysis by expression of CD55 and CD59.  Eur J Immunol
2003, 33:522-531.
19. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof
ME: Decay-accelerating factor modulates induction of T cell
immunity.  J Exp Med 2005, 201:1523-1530.
20. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, Song WC:
The complement inhibitory protein DAF (CD55) suppresses
T cell immunity in vivo.  J Exp Med 2005, 201:567-577.
21. Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, Werth VP,
Madaio MP, Eisenberg RA, Song WC: Deletion of decay-acceler-
ating factor (CD55) exacerbates autoimmune disease devel-
opment in MRL/lpr mice.  Am J Pathol 2002, 161:1077-1086.
22. Holers VM: The complement system as a therapeutic target
in autoimmunity.  Clin Immunol 2003, 107:140-151.
23. Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, Pociot F,
Todd JA, Rich SS: Type 1 diabetes: evidence for susceptibility
Loci from four genome-wide linkage scans in 1,435 multiplex
families.  Diabetes 2005, 54:2995-3001.
24. Cox NJ, Wapelhorst B, Morrison VA, Johnson L, Pinchuk L, Spielman
RS, Todd JA, Concannon P: Seven regions of the genome show
evidence of linkage to type 1 diabetes in a consensus analysis
of 767 multiplex families.  Am J Hum Genet 2001, 69:820-830.
25. International HapMap Project   [http://www.hapmap.org]
26. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly
P:  A haplotype map of the human genome.  Nature 2005,
437:1299-1320.
27. Wang WY, Todd JA: The usefulness of different density SNP
maps for disease association studies of common variants.
Hum Mol Genet 2003, 12:3145-3149.
28. Chapman JM, Cooper JD, Todd JA, Clayton DG: Detecting disease
associations due to linkage disequilibrium using haplotype
tags: a class of tests and the determinants of statistical
power.  Hum Hered 2003, 56:18-31.
29. Clayton D, Chapman J, Cooper J: Use of unphased multilocus
genotype data in indirect association studies.  Genet Epidemiol
2004, 27:415-428.
30. Clayton DG, Walker NM, Smyth DJ, Pask R, Cooper JD, Maier LM,
Smink LJ, Lam AC, Ovington NR, Stevens HE, Nutland S, Howson JM,
Faham M, Moorhead M, Jones HB, Falkowski M, Hardenbol P, Willis
TD, Todd JA: Population structure, differential bias and
genomic control in a large-scale, case-control association
study.  Nat Genet 2005, 37:1243-1246.
31. Swarbrick MM, Vaisse C: Emerging trends in the search for
genetic variants predisposing to human obesity.  Curr Opin Clin
Nutr Metab Care 2003, 6:369-375.
32. Fearnhead NS, Winney B, Bodmer WF: Rare variant hypothesis
for multifactorial inheritance: susceptibility to colorectal
adenomas as a model.  Cell Cycle 2005, 4:521-525.
33. Storry JR, Sausais L, Hue-Roye K, Mudiwa F, Ferrer Z, Blajchman MA,
Lublin DM, Ma BW, Miquel JF, Nervi F, Pereira J, Reid ME: GUTI: a
new antigen in the Cromer blood group system.  Transfusion
2003, 43:340-344.
34. Telen MJ, Rao N, Udani M, Thompson ES, Kaufman RM, Lublin DM:
Molecular mapping of the Cromer blood group Cra and Tca
epitopes of decay accelerating factor: toward the use of
recombinant antigens in immunohematology.  Blood 1994,
84:3205-3211.
35. Daniels GL, Green CA, Darr FW, Anderson H, Sistonen P: A 'new'
Cromer-related high frequency antigen probably antitheti-
cal to WES.  Vox Sang 1987, 53:235-238.
36. Sistonen P, Nevanlinna HR, Virtaranta-Knowles K, Tuominen I,
Pirkola A, Green CA, Tippett P: WES, a 'new' infrequent blood
group antigen in Finns.  Vox Sang 1987, 52:111-114.
37. Lindahl G, Sjobring U, Johnsson E: Human complement regula-
tors:a major target for pathogenic microorganisms.  Curr Opin
Immunol 2000, 12:44-51.
38. Liszewski MK, Post TW, Atkinson JP: Membrane cofactor protein
(MCP or CD46): newest member of the regulators of com-
plement activation gene cluster.  Annu Rev Immunol 1991,
9:431-455.
39. Power C, Elliott J: Cohort profile: 1958 British birth cohort
(National Child Development Study).  Int J Epidemiol 2006,
35:34-41.
40. Bain SC, Todd JA, Barnett AH: The British Diabetic Association–
Warren repository.  Autoimmunity 1990, 7:83-85.
41. Lernmark A, Ducat L, Eisenbarth G, Ott J, Permutt MA, Rubenstein
P, Spielman R: Family cell lines available for research.  Am J Hum
Genet 1990, 47:1028-1030.
42. Burren OS, Healy BC, Lam AC, Schuilenburg H, Dolman GE, Everett
VH, Laneri D, Nutland S, Rance HE, Payne F, Smyth D, Lowe C, Bar-
ratt BJ, Twells RC, Rainbow DB, Wicker LS, Todd JA, Walker NM,
Smink LJ: Development of an integrated genome informatics,
data management and workflow infrastructure: a toolbox
for the study of complex disease genetics.  Hum Genomics 2004,
1:98-109.
43. Smink LJ, Helton EM, Healy BC, Cavnor CC, Lam AC, Flamez D, Bur-
ren OS, Wang Y, Dolman GE, Burdick DB, Everett VH, Glusman G,
Laneri D, Rowen L, Schuilenburg H, Walker NM, Mychaleckyj J,
Wicker LS, Eizirik DL, Todd JA, Goodman N: T1DBase, a commu-
nity web-based resource for type 1 diabetes research.  Nucleic
Acids Res 2005:D544-549.
44. Gbrowse   [http://www.gmod.org/]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
Page 9 of 9
(page number not for citation purposes)
45. T1DBase   [http://t1dbase.org/cgi-bin/dispatcher.cgi/Welcome/dis
play]
46. Bonfield JK, Rada C, Staden R: Automated detection of point
mutations using fluorescent sequence trace subtraction.
Nucleic Acids Res 1998, 26:3404-3409.
47. Lowe CE, Cooper JD, Chapman JM, Barratt BJ, Twells RC, Green EA,
Savage DA, Guja C, Ionescu-Tirgoviste C, Tuomilehto-Wolf E,
Tuomilehto J, Todd JA, Clayton DG: Cost-effective analysis of
candidate genes using htSNPs: a staged approach.  Genes
Immun 2004, 5:301-305.
48. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG:
Genetic associations in large versus small studies: an empir-
ical assessment.  Lancet 2003, 361:567-571.
49. Service SK, Sandkuijl LA, Freimer NB: Cost-effectivedesigns for
linkage disequilibrium mapping of complex traits.  Am J Hum
Genet 2003, 72:1213-1220.
50. JDRF/WT Diabetes and Inflammation Laboratory   [http://
www-gene.cimr.cam.ac.uk/clayton/software/stata]
51. Ranade K, Chang MS, Ting CT, Pei D, Hsiao CF, Oliver M, Pesich R,
Hebert J, Chen YD, Dzau VJ, Curb D, Olshen R, Risch N, Cox DR,
Botstein D: High -throught genotyping with single nucleotide
polymorphisms.  Genome Res 2001, 11:1262-1268.